Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $67.76 USD
Change Today +0.59 / 0.88%
Volume 1.3M
ISIS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

isis pharmaceuticals inc (ISIS) Snapshot

Open
$66.84
Previous Close
$67.17
Day High
$68.09
Day Low
$66.50
52 Week High
03/20/15 - $77.80
52 Week Low
06/4/14 - $26.57
Market Cap
8.1B
Average Volume 10 Days
1.7M
EPS TTM
$-0.08
Shares Outstanding
119.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ISIS PHARMACEUTICALS INC (ISIS)

isis pharmaceuticals inc (ISIS) Related Businessweek News

View More BusinessWeek News

isis pharmaceuticals inc (ISIS) Details

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 38 drugs in development for the treatment of various diseases, including cardiovascular and metabolic diseases; severe and rare diseases, which include neurological disorders; and cancer. The company has strategic alliances and collaboration agreements primarily with AstraZeneca AB, Biogen Idec MA Inc., Bristol-Myers Squibb, Eli Lilly and Company, Genzyme Corporation, Hoffman-La Roche Inc., F. Hoffmann-La Roche Ltd., Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Excaliard Pharmaceuticals, Inc., OncoGenex Technologies Inc., Janssen Biotech, Inc., and Atlantic Pharmaceuticals Limited. Isis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

390 Employees
Last Reported Date: 03/2/15
Founded in 1989

isis pharmaceuticals inc (ISIS) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $1.5M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $584.6K
Chief Operating Officer, Director and Member ...
Total Annual Compensation: $1.1M
Senior Vice President of Development
Total Annual Compensation: $636.1K
Senior Vice President of Antisense Research
Total Annual Compensation: $631.6K
Compensation as of Fiscal Year 2014.

isis pharmaceuticals inc (ISIS) Key Developments

Isis Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

Isis Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of USD 62,583,000 compared to USD 28,161,000 a year ago. Loss from operations was USD 9,330,000 compared to USD 29,667,000 a year ago. Loss before income tax benefit was USD 17,506,000 compared to USD 33,556,000 a year ago. Net loss was USD 16,717,000 or USD 0.14 per basic and diluted share compared to USD 31,280,000 or USD 0.27 per basic and diluted share a year ago. Pro forma income from operations was USD 3,975,000 compared to pro forma loss from operations of USD 22,598,000 a year ago. Pro forma net loss was USD 3,412,000 compared to USD 24,211,000 a year ago. Net loss was decreased primarily due to an increase in revenue from milestone payments. With continuing opportunities to earn additional milestone payments from its partners as he company progress through the year 2015, puts on track to exceed its guidance of a pro forma net operating loss in the mid USD 50 million range and more than USD 630 million in cash.

Isis Pharmaceuticals, Inc. Enters into Exclusive License Agreement with Bayer Healthcare to Develop and Commercialize ISIS-FXIRx for the Prevention of Thrombosis

Isis Pharmaceuticals, Inc. entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention of thrombosis. Under the terms of the agreement, the company is eligible to receive up to $155 million in near-term payments, including an immediate $100 million up-front payment and a $55 million payment upon advancement of the program following a Phase 2 study in patients with compromised kidney function. Isis is also eligible to receive milestone payments as the drug advances toward the market. In addition, Isis is eligible to receive tiered royalties in the low to high 20% range on gross margins of ISIS-FXIRx. After completion of ongoing activities at Isis, Bayer will assume all global clinical development as well as worldwide regulatory and commercialization responsibilities for ISIS-FXIRx. As part of the clinical development program, Bayer plans to evaluate the therapeutic profile of ISIS-FXIRx in patients for whom currently available anticoagulants may not be used, such as in patients with a high risk of bleeding due to multiple co-morbidities. This transaction is subject to clearances under the Hart-Scott Rodino Antitrust Improvements Act.

Isis Pharmaceuticals Reports Positive Data from ISIS-TTR Rx in Patients With TTR Amyloidosis

Isis Pharmaceuticals, Inc. announced positive data from an ongoing open-label extension (OLE) study of ISIS-TTR Rx in patients with familial amyloid polyneuropathy (FAP). FAP patients completing the ongoing Phase 3 study are eligible to enroll in this OLE study in which all patients receive ISIS-TTRRx. An analysis conducted on the first group of patients to reach three months of treatment in the OLE study showed a reduction in transthyretin (TTR) protein levels up to 92% with a median reduction of 78% compared to patients' baseline TTR levels at entry into the Phase 3 study. Patients continue to be enrolled as they complete dosing in the Phase 3 study.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $67.76 USD +0.59

ISIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $40.55 USD +0.33
Acorda Therapeutics Inc $32.01 USD -0.25
Aegerion Pharmaceuticals Inc $20.38 USD -0.24
Depomed Inc $20.76 USD +0.51
View Industry Companies
 

Industry Analysis

ISIS

Industry Average

Valuation ISIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 32.4x
Price/Book 29.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 27.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit www.isispharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.